Evidence map›Paper›PMID 35098699›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022

Acid-Degradable Hydrogen-Generating Metal-Organic Framework for Overcoming Cancer Resistance/Metastasis and Off-Target Side Effects.

Xianxian Yao, Danyang Chen, Bin Zhao, Binru Yang, Zhaokui Jin, Mingjian Fan, Geru Tao, Shucun Qin, Wuli Yang, Qianjun He

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  6. Review
  7. Research progress in clinical utilization of HFrontiers in pharmacology · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Xianxian YaoState Key Laboratory of Molecular Engineering of Polymers and Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.
Danyang ChenSchool of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, Guangdong, 518060, China.
Bin ZhaoSchool of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, Guangdong, 518060, China.
Binru YangState Key Laboratory of Molecular Engineering of Polymers and Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.
Zhaokui JinSchool of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, Guangdong, 518060, China.
Mingjian FanSchool of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, Guangdong, 518060, China.
Geru TaoInstitute of Atherosclerosis, Taishan Institute for Hydrogen Biological Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, Shandong, 271000, China.
Shucun QinInstitute of Atherosclerosis, Taishan Institute for Hydrogen Biological Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, Shandong, 271000, China.
Wuli YangState Key Laboratory of Molecular Engineering of Polymers and Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.
Qianjun HeSchool of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, Guangdong, 518060, China.ORCID 0000-0003-0689-8838
Fudan University · CNShenzhen University Health Science Center · CNShanghai Jiao Tong University · CNTaishan Medical University · CN

Funding

Center of Hydrogen Science, Shanghai Jiao Tong University, ChinaHigh-Level University Construction Project of Health Science Center, Shenzhen University 860-00000210National Key R&D Program of China 2016YFC1100300Natural Science Foundation of China 51872188Natural Science Foundation of China 51873041Natural Science Foundation of China 51933002Program of Shanghai Academic Research Leader 20XD1400400Shenzhen Basic Research Program JCYJ20170302151858466Shenzhen Basic Research Program JCYJ20170818093808351Special Funds for the Development of Strategic Emerging Industries in Shenzhen 20180309154519685
6 · The paper itself

Abstract

The development of stimuli-responsively degradable porous carriers for both controlled drug release and high biosafety is vitally important to their clinical translation, but still challenging at present. A new type of porphyrin-iron metal organic framework (Fe-MOF) nanocrystals is engineered here as acid-degradable drug carrier and hydrogen donor by the coordination between porphyrin and zero-valence Fe atom. Fe-MOF nanocrystals exhibit excellent acid-responsive degradation for H

Indexed as

Metal-Organic FrameworksNeoplasmsDrug CarriersDrug Resistance, MultipleHydrogenMatrix Metalloproteinase 2Drug CarriersHydrogenMatrix Metalloproteinase 2Metal-Organic Frameworkscontrolled releasedrug deliveryhydrogen therapymetal-organic frameworkmetastasismultidrug resistancenanomedicine

Identifiers

PMID35098699
PMCPMC8981430
OpenAlexW4210593463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.